DLL3 and small cell lung carcinoma: The SCLC-A subtype has a high expression of ASCL1, so its level of DLL3 is significantly higher than that of other subtypes, accounting for approximately 50-60% of all SCLC, providing an enriched “target population” for DLL3-targeted therapy.